Coolstock, what about a deal with Gradalis?
If the FDA gives Gradalis a "Breakthrough" designation then they can sell the treatment to patients treated after the approval has been given--and approval may have already been given. This means Gradalis will have moved out of the "safe haven" patent protection that it has enjoyed to-date.
Under these circumstances they may want to finalise any IP issues before advertising for more patients. So, if we are ever to do a deal without resorting to litigation, then some time over the next 6-9 months would be the time.
What would an announcement about Gradalis licencing our technology do to your timetable? How would you know just when the sp would take-off?
what could happen if tt-034 is successful, page-17
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)